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erbation of renal tubule ultrastructure injury and greater activation of Akt
and ERK1/2 phosphorylated signaling. Conversely, treatment with hrACE2
signiﬁcantly attenuated renal oxidative stress levels and ultrastructure
injury, and prevented the expression of NOX4 and phosphorylated level
of Akt and ERK1/2 in ApoEKO mouse kidneys. However, there were no
changes in renal expression of NOX2 among groups.
CONCLUSIONS Deletion of ACE2 triggers greater increases in renal
oxidative stress and tubular ultrastructure injury in the ACE2/ApoE
double mutant mice with greater activation of Akt-ERK1/2 phos-
phorylated signaling. While ACE2 overexpression alleviates renal
tubular injury in ApoE-mutant mice with suppression of superoxide
generation and downregulation of the Akt-ERK phosphorylated
signaling. Strategies aimed at enhancing ACE2 action may have
important therapeutic potential for atherosclerosis and renal diseases.
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OBJECTIVES Genetic predisposition plays an important role amidst
the other risk factors in the development of atherosclerosis, a socially
signiﬁcant multifactorial disease. This study was aimed to identify
the relationship between mitochondrial DNA (mtDNA) variants and
the presence of subclinical atherosclerosis, which was deﬁned ultra-
sonographically as the abnormal increase of intima-media thickness of
common carotid arteries (cIMT).
METHODS For the accurate detection of mtDNA variants, high-
throughput sequencing of the mitochondrial genome from blood
leukocytes using the Roche 454 technology was carried out in 77
asymptomatic non-related subjects. To assess the state of the carotid
artery wall, high-resolution B-mode ultrasonography was performed
with ultrasound scanner SonoScape SSI-1000 (China) using a linear
vascular 7.5 MHz probe. The borderline values for Russian population
were used for detection of abnormal cIMT values.
RESULTS In patients with subclinical atherosclerosis, 70 mtDNA
variants have been revealed that were characterized by the prevalence
over 5% of the total sample or among patients or controls. Twenty-ﬁve
of them occurred in coding region, and 5 were located in rRNA genes,
3 in tRNA genes, 5 were missense mutations. For 5 variants charac-
terized by the increased frequency in healthy subjects there were
signiﬁcant differences from the patients with subclinical atheroscle-
rosis. Three homoplasmic mtDNA variants were found only in patients
with atherosclerosis. Six MtDNA variants were characterized by a
more than 2-fold increased frequency in patients with subclinical
atherosclerosis as compared to healthy subjects. As for 115 hetero-
plasmic mtDNA variants revealed, 15 were found both in healthy
subjects and patients with subclinical carotid atherosclerosis. Three
variants had higher frequency in healthy subjects, and two variants
had higher frequency in patients with subclinical atherosclerosis.
CONCLUSIONS The data obtained in our study can be used to assess
individual risk of atherosclerosis and for further studies on the role of
mitochondrial genome mutations in the development of atheroscle-
rosis and its clinical manifestations. The individual proﬁle of certain
mtDNA variants may partially explain atherosclerosis variability and
genetic predisposition to atherosclerosis in population, which could
be inherited by maternal line.
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OBJECTIVES Long non-coding RNAs (lncRNAs) have been found to be
involved in coronary artery disease (CAD) development. Whether ornot circulating lncRNAs work as a CAD biomarker, needs to be
established.
METHODS Using microarray-based lncRNA expression proﬁling to
explore the lncRNA expression in the circulating peripheral blood
monocyte (PBMCs) and plasma from 15 CAD patients and 15 control
subjects. After criteria (average normalized intensity is more than 7
with signiﬁcance less than 0.005) based selection, and conﬁrmed by
quantitative RT-PCR. Using the analysis of the area under the curve
(AUC) of the receiver operating characteristic (ROC) in large amount of
population. Functional enrichment analysis was performed by GO and
pathway analysis. Further validation using the speciﬁc siRNA in the
THP-1 cell line, and the concentrations of pro-inﬂammatory cytokines
(IL-1b, IL-6 and TNFa) in the culture media, were studied by ELISA.
RESULTS According to the array in the PBMCs and plasma, we found
86 lncRNAs that were differentially expressed in both PBMCs and
plasma from 15 CAD patients and 15 control subjects. After criteria and
conﬁrmed by quantitative RT-PCR, only three lncRNAs (CoroMarker,
BAT5 and IL21R-AS1) remained in the select candidate list. By ROC
analysis, CoroMarker was found to be the best candidate biomarker
for CAD with an AUC of 0.920, 95% CI 0.892-0.947. CoroMarker was
independent from CAD risk factors and other cardiovascular diseases.
In a prospective study, we found the sensitivity and speciﬁcity of
CoroMarker were 76% and 92.5%, respectively. Functional enrichment
analysis showed CoroMarker being clustered with small molecule
metabolic process and the signal transduction signaling pathway.
Further validation using the speciﬁc siRNA in the THP-1 cell line, the
concentrations of pro-inﬂammatory cytokines (IL-1b, IL-6 and TNFa)
in the culture media, were reduced signiﬁcantly.
CONCLUSIONS The present study suggests that CoroMarker have an
unanticipated role in inﬂammatory response to ﬁnally impact in the
risk of CAD, and be a novel and speciﬁc functional biomarker for the
diagnosis of CAD.GW26-e1064
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OBJECTIVES Our previous study conﬁrmed that in heart failure the
expression and function of SK channels upregulated signiﬁcantly and
participated in electrical remodeling of cardiocytes, but the regulation
of SK channels was poorly understood in this process. Studies indi-
cated that the sensitivity of SK channels to [Ca2þ]i is positively
regulated by PP2A, which is activated by angiotensin II in many bio-
logical response paths. In the present study, we explored the effect of
angiotensin converting enzyme inhibitor captopril on apamin sensi-
tive SK channels in HF.
METHODS We used volume-overload induced heart failure rat model
by aortocaval ﬁstulas (HF group), and captopril was administrated by
gavage (CAF group). Whole-cell patch clamp was performed to
recording IKAS (Apamin sensitive current), and I-V curve was applied
to determine the the effect of captopril on IKAS. We also explored the
effect of captopril on the sensitivety of SK channels to [Ca2þ]i by
setting various [Ca2þ]i (10, 100, 500, 900,10,000 nM) at single isolated
cells, and the Hill equation (y¼1/[1þ (EC50/x)n]) was employed to
ﬁtted currents data(EC50 represents the [Ca2þ]i concentration at
halfmaximal activation of IKAS, n represents the Hill coefﬁcient). And
immunoﬂuorescent staining, real time PCR, western blot were also
carried out to furtherly investigate the underlying molecular mecha-
nism of the regulation.
RESULTS Captopril signiﬁcantly decreased the mean IKAS density at
0 mV (CAF 5.40  1.11 pA/pF, n ¼ 6 cells from 5 rats vs HF 8.90  1.79
pA/pF, n ¼ 5 cells from 6 rats P<0.05) when [Ca2þ]i at 900 nM
comparing with HF group, and obviously shifted down the I-V curve.
Similarly, the IKAS density was markedly downregulated by captopril
when [Ca2þ]i at 500, 1000, 10000nM (500 nM: CAF 4.21  0.16 pA/pF,
n ¼ 6 cells from 4 rats vs HF 7.98  0.43 pA/pF, n ¼ 6 cells from 6 rats
P<0.05; 1000nM: CAF 5.51  0.71 pA/pF, n ¼ 6 cells from 6 rats vs HF
8.96  0.51 pA/pF, n ¼ 6 cells from 5 rats P<0.05; 10000nM: CAF 5.80
 0.52 pA/pF, n ¼ 5 cells from 3 rats vs HF 9.02  0.57 pA/pF, n ¼ 5
cells from 4 rats P<0.05), the data of the Hill ﬁtting showed the sig-
niﬁcant difference in EC50 values and the Hill coefﬁcients among
the three group cells (EC50 CAF 313  17 nM, HF 231  11 nM, P<0.05;
